Background
Intravaginal practices (IVPs) are behaviours undertaken by women in diverse global settings for the promotion of hygiene and sexual health. Although evidence is inconclusive, it has been suggested that they may be harmful and associated with adverse gynaecological outcomes. The objective of this study was to investigate whether there is an association between IVPs, human papillomavirus (HPV) infection and the development of cervical cancer. As human immunodeficiency virus (HIV) infection may be a factor accelerating progression, recent evidence on the association between IVPs and HIV was also considered.

Methods
A systematic review of primary observational studies was carried out according to PRISMA (Preferred Reporting Items for Systematic Reviews) guidelines. A detailed search strategy was developed and modified for use in six databases and grey literature sources, searching from 01 January 1990 to 03 June 2019. Due to marked heterogeneity, narrative synthesis was used to combine findings.

Results
Twenty studies met the review criteria. The majority of studies were cross-sectional, and of moderate to low quality. A total of 14,493 participants were included, from 15 countries. IVP prevalence ranged from below 10% to over 90% across study populations. Six of eleven studies found an increased risk of HPV infection with IVPs; five of seven studies found an increased risk of cervical disease with IVPs. Two studies examining association of IVPs with risk of HIV infection were identified: both found associations with intravaginal cleansing, one found an association with intravaginal insertion. Potential moderator variables including the types of substances used, the frequency, timing and duration of IVP use were assessed: evidence was conflicting and inconsistent.

Conclusions
Current evidence is largely suggestive of a harmful association between IVPs and the development of cervical cancer. However, significant methodological limitations were recognised; there is a need for well-designed studies using consistent definitions and classifications.
in women worldwide, particularly in sub-Saharan Africa and Central and South America.\textsuperscript{10} HPV infection as the necessary cause of cervical cancer, follows a well-understood pathway to progression, through infection and persistence of high-risk subtypes, to pre-cancerous changes and subsequent invasive cervical cancer.\textsuperscript{11} The initiation of HPV infection is thought to be facilitated by micro-trauma in the cervical epithelium.\textsuperscript{12} Some factors have been associated with an elevated cervical cancer risk in women with HPV-infection, such as long-term oral contraceptive use, smoking and other sexually transmitted infection (STI) co-infection.\textsuperscript{13} Additionally, HIV is recognised as a significant contributor to cervical cancer progression due to immunosuppression.\textsuperscript{14,15} As IVPs are often described in regions with high prevalence of HIV, HPV infection and cervical cancer, it is critical to continue to ascertain the possibility of risk associated with use of IVPs and HIV infection. These potential associations are illustrated (Figure 1).

**Box 1. Classification of Intravaginal Practices.**

The WHO Gender, Sexuality and Vaginal Practices (GSVP) Study Group\textsuperscript{1} proposed a classification for vaginal practices, of which only those that potentially have an effect on the vaginal mucosa have been described below:

- **Intravaginal cleansing:** Cleaning inside the vagina to remove excess fluid, which can include wiping or washing the genitalia internally using fingers or materials such as cotton wool or cloths. Douching, in which water or another solution is pumped into the vagina under pressure is also included in this.
- **Intravaginal insertion:** Placement of external products into the vagina, independent of duration.
- **Oral ingestion** of substances that are believed to have an effect on the vagina.
- **Vaginal steaming or smoking:** Involves sitting over a heat source with steam created by oils, herbs and water.
- **Anatomical modifications** (self-administered): Introitus incision with herbs or traditional medicines inserted into the lesion.\textsuperscript{2}

Other external practices such as external washing and external application have been excluded.

We describe a systematic review to assess the evidence of an association of IVPs with HPV infection, and the development of cervical cancer, using ‘cervical disease’ as an overarching term to encompass pre-cancerous changes and cervical cancer.

**OBJECTIVES**

In order to examine whether intravaginal practices are associated with HPV infection and cervical cancer development, we systematically reviewed primary observational studies covering a range of IVPs in different geographical regions and their associations with HPV infection and cervical disease. Additionally, we examined recent evidence describing any association of IVPs with HIV infection.

**METHODS**

**PROTOCOL AND REGISTRATION**

A protocol was developed using the Preferred Reporting Items for Systematic Review and Meta-Analysis-Protocol (PRISMA-P) guidelines\textsuperscript{16} and is provided in Online Supplementary Document.

**ELIGIBILITY CRITERIA**

Studies eligible for inclusion were cohort, case-control and cross-sectional studies, investigating the relationship between intravaginal practices in women of all ages in any global setting and cervical HPV, cervical disease or HIV infection. A broad definition of IVPs was adopted, taking the practices as defined by the individual study authors but excluding practices that were only external or were not self-administered. Where IVPs were examined as part of a risk factor profile, studies were eligible provided IVPs were analysed separately with effect measures given. No restrictions were placed on the purpose for conducting IVPs. Any studies that considered sexually transmitted infections in general without the specific mention of HPV or HIV infections were excluded. No location or language were specified to ensure the range of geographical variation was captured. In relation to date of publication, only studies published after 1990 were considered for HPV and only after 2008 for HIV due to the prior systematic reviews on the topic including studies published prior to this date. Both published and unpublished studies were eligible for inclusion.

**LITERATURE SEARCHES**

A comprehensive search strategy, devised with the help of a University of Edinburgh health sciences librarian, was adapted for use in six electronic databases, namely MEDLINE (Ovid Interface), EMBASE (Ovid Interface), Global Health (Ovid Interface), Cumulative Index to Nursing and Allied Health Literature (CINAHL, EBSCOhost), POPLINE (Population Information Online) and Web of Science, from 01 January 1990 to the 03 June 2019. Additionally, grey literature sources including OpenGrey, the Grey Literature Report, the WHO African Region Library and ProQuest Dissertations and Theses were searched and the reference lists of all full-texts for inclusion were scanned to identify any other relevant studies. Briefly, search terms were a combination of Medical Subject Headings (MeSH) and free text terms based on variations of the exposure and outcome of interest; namely 'intravaginal practice', 'vaginal douching', 'intravaginal insertion', 'intravaginal cleansing', 'hygiene', 'application', 'modification', 'dry sex', 'human papillomavirus', 'cervical dysplasia', 'human immunodeficiency virus' and 'sexually transmitted infection'. The detailed search strategy is available in Online Supplementary Doc-
Are intravaginal practices associated with human papillomavirus and the development of cervical cancer? A systematic...
versity of Edinburgh.

RESULTS

STUDY SELECTION

Figure 2 shows the PRISMA diagram, illustrating the study selection. An initial 3,185 records were identified, of which 2,021 remained after de-duplication. After title and abstract screening, 42 records underwent full-text screening: 18 studies in 21 records were identified as eligible for inclusion. A further two studies were identified through scanning the reference lists of included studies, leading to a total of 20 studies in 23 records for analysis. A full list of excluded studies and reasons for exclusion is provided in Online Supplementary Document.

STUDY CHARACTERISTICS

The characteristics of individual studies are described in Table 1, categorised according to outcome. Thirteen studies were cross-sectional,23–35 five were cohort studies36–40 and two were case-control studies,41,42 published between 1991 and 2018. In total, they accounted for 14,493 participants. Nine studies were carried out in sub-Saharan Africa (Democratic Republic of the Congo (DRC), Malawi, Mali, Nigeria, South Africa, Tanzania, Uganda, Zimbabwe), five in Asia (Cambodia, China, South Korea, Taiwan), four in the United States of America (USA), one in Haiti and one in Brazil. The majority (12 studies) included participants recruited from health care settings such as clinics and hospitals,28,32–42 and four23,25–27 were based on female sex worker (FSW) cohorts. One study included adolescent participants before reported sexual debut.29

IVPs described varied in description, detail and substances used (if recorded). Douching was most commonly studied, analysed in ten studies, with three from Asia,30,32,37 three from the USA,33,38,41 two from sub-Saharan Africa,25,42 one from Haiti41 and one from Brazil.40 However, a definition in keeping with that proposed by the WHO GSVP1 was only provided in one study42 while the others solely stated douching as the IVP under investigation. Two other studies which were reportedly evaluating douching had definitions more aligned with general intravaginal cleansing and were hence analysed with this group.24,26 Intravaginal cleansing and intravaginal insertion were heavily skewed towards sub-Saharan Africa, described in seven studies from this region27–29,34–36,39 and in one additional study from Cambodia.23
| Author, year of publication | Country     | Study design | Participants                                                                 | Age          | Intravaginal practice                                                        | Outcome                                                                 | Study quality* |
|-----------------------------|-------------|--------------|-------------------------------------------------------------------------------|--------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------|----------------|
| Bui et. al, 2018            | Cambodia    | Cross-sectional | 200 FSWs                                                                    | Mean 26.7    | Intravaginal washing Intravaginal wiping Intravaginal insertion              | HPV infection (number of infecting HPV genotypes)                      | Moderate       |
|                             |             |              |                                                                               | Range 18 – 35|                                                                              |                                                                         |                |
| Bui et. al, 2016            | USA         | Cross-sectional | 1271 women participating in a national survey                                | Range 20 – 49| Douching†                                                                    | HPV infection (number of infecting HPV DNA types)                      | Moderate       |
| Ebrahim et. al, 2016        | South Africa| Cohort        | 224 young women attending primary health care clinics                        | Median 21    | Vaginal insertion practices                                                  | HPV prevalence                                                      | Moderate       |
|                            |             |              |                                                                               | Range 14 – 30|                                                                              |                                                                         |                |
| Esber et. al, 2016 (full publication) | Malawi   | Cross-sectional | 200 care-seeking women                                                       | Median 33    | Intravaginal cleansing Intravaginal insertion                               | High-risk HPV infection, bacterial vaginosis, HSV-2 infection          | Moderate       |
|                            |             |              |                                                                               |              |                                                                              |                                                                         |                |
| Houlihan et. al, 2014 (full publication) | Tanzania | Cross-sectional | 474 adolescent girls before reported sexual debut                            | Range 15 – 16| Intravaginal cleansing Intravaginal insertion                               | HPV infection                                                      | Moderate       |
|                            |             |              |                                                                               |              |                                                                              |                                                                         |                |
| Lee et. al, 2014            | South Korea | Cross-sectional | 912 women in a twin cohort                                                   | Range 25 – 79| Douching                                                                      | HPV infection                                                      | Moderate       |
|                            |             |              |                                                                               |              |                                                                              |                                                                         |                |
| Mosicki et. al, 2013        | USA         | Cohort        | 1543 women, part of an HPV natural history study recruited from clinic sites | Range 13 – 21| Douching                                                                      | HPV16 DNA redetection on cervical sample                                | High           |
|                            |             |              |                                                                               |              |                                                                              |                                                                         |                |
| Seay et. al, 2017 (full publication) | Haiti    | Cross-sectional | 416 women recruited by Community Health Workers                             | Range 26 – 40| “Twalet deba”, Haitian Creole term, use of agents and water to produce an infusion for douching | High-risk HPV infection                                                | High           |
|                            |             |              |                                                                               |              |                                                                              |                                                                         |                |
| Shaw et. al, 2016           | Brazil      | Cohort        | 1867 women recruited from a maternal and child health program               | Mean 32.9    | Douching                                                                      | HPV 1-year period prevalence; transient HPV infection, persistent HPV infection | Moderate       |
|                            |             |              |                                                                               |              |                                                                              |                                                                         |                |
| Sun et. al, 2005            | Taiwan      | Cross-sectional | 1264 women attending gynaecologic clinics, with abnormal cervical cytology   | Median 44    | Douching, post-coital                                                        | HPV prevalence                                                      | Low            |
|                            |             |              |                                                                               | Range 16 – 85|                                                                              |                                                                         |                |
| Tarkowski et. al, 2004      | USA         | Cross-sectional | 312 urban adolescent girls recruited from a clinic                           | Mean 16.1    | Douching                                                                      | HPV infection                                                      | Low            |
| Author, year of publication | Country | Study design | Participants | Age | Intravaginal practice | Outcome | Study quality* |
|-----------------------------|---------|--------------|--------------|-----|-----------------------|---------|---------------|
| Ali-Risasi et. al, 2015     | DRC     | Cross-sectional | 1018 women recruited from HIV screening centres, hospitals & health centres | Mean 43.0 Range 17 – 82 | Intravaginal application of plants/vegetable products or chemicals for vaginal care | LSIL or worse | Moderate |
| Bayo et. al, 2002           | Mali    | Case-control | Hospital-based; 82 cases (invasive cervical cancer), 97 hospital controls matched by 5-year age groups | Mean 47 Range 25 – 56 and older | Douching | Invasive cervical cancer | Moderate |
| Chu et. al, 2011            | Taiwan  | Cohort       | 1332 women with abnormal Pap smear results in medical centres, follow-up of 295 with colposcopy-confirmed LSIL | Not stated | Douching, post-coital | LSIL non-regression, LSIL progression | High |
| Gardner et. al, 1991        | USA     | Case-control | 266 cases (in-situ and invasive cervical carcinoma), 408 group-matched controls | Range 20 – 59 | Douching | In-situ and invasive cervical carcinoma | Moderate |
| Mbizvo et. al, 2005         | Zimbabwe| Cross-sectional | 200 Mother and Child Health clinic attendees | Range 15 – 49 | Intravaginal cleansing Use of intravaginal herbs | Cervical dyskaryosis (mild, moderate, severe) | Low |
| Sagay et. al, 2009          | Nigeria | Cross-sectional | 374 FSWs recruited from brothels in the urban centre of Jos | Mean 27.8 Range 16 – 63 | Douching | Cervical dysplasia, SILs | Low |
| van de Wijgert et. al, 2000 | Zimbabwe| Cohort        | 169 women recruited from family planning, primary care and postnatal clinics | Mean age 30 Range 18 – 45 | Finger-cleansing, wiping and inserting traditional substances | Colposcopic lesions, HIV & other STIs, dysplasia on Pap smear (CIN I to III or invasive cervical cancer) | Moderate |
| Luo et. al, 2016            | China   | Cross-sectional | 837 FSWs | Median 23 Range 16 – 52 | Douching† | HIV/STIs (N. gonorrhoeae, C. trachomatis, T. pallidum, T. vaginalis, HSV-2 seropositive) | Moderate |
| Vandepitte et. al, 2011     | Uganda  | Cross-sectional | 1027 women with high-risk sexual behaviour (commercial sex work or employed in entertainment facilities) | Mean age 26 | Vaginal cleansing | HIV seroprevalence | High |

*CQuality assessment was carried out using the Appraisal Tool for Cross-Sectional Studies (AXIS), and the Newcastle-Ottawa Scale (NOS) for case-control and cohort studies

†Included in intravaginal cleansing group for analysis

CIN – cervical intraepithelial neoplasia; DRC – Democratic Republic of the Congo; FSW – female sex worker; HIV – human immunodeficiency virus; HPV – human papillomavirus; HSV-2 – Herpes simplex virus type 2; LSIL – low-grade squamous intraepithelial lesion; SIL – squamous intraepithelial lesion; STI – sexually transmitted infection; USA – United States of America
Substances were frequently water-based with the addition of natural and commercial products such as salt, lemon or lime juice, vinegar, plant-based agents, medical disinfectant, toothpaste and soap.\textsuperscript{25,29,26,28,29,34,37} The purpose for conducting IVPs where recorded was cited as hygiene most frequently, both for general cleanliness and around sexual intercourse.\textsuperscript{26,27,41} Other reasons were for infection prevention or management and for contraception.\textsuperscript{25–27,41} Intravaginal insertion was practised using herbs acquired from traditional healers, alum, tobacco and other powders, castor oil and medications, with the main purpose being for drying, tightening and warming the vagina prior to sexual intercourse.\textsuperscript{27–29,36,39} The method of application was only mentioned in three studies, commonly the use of fingers, cotton wool or cloth.\textsuperscript{28,29,36}

Studies assessed IVPs in relation to the three outcomes of interest; 11 examined HPV infection, seven examined cervical disease and two examined HIV infection, in all cases either as the primary focus or as part of an assessment of multiple risk factors.

QUALITY ASSESSMENT

Using the AXIS tool, which comprises a checklist of 20-items for overall assessment without the assignment of a score, two cross-sectional studies were assessed as high quality.\textsuperscript{29,31} seven as moderate\textsuperscript{25,24,26,28–30,34} and four as low quality.\textsuperscript{25,32,33,35} Using the NOS, the included case-control studies were both assessed as moderate quality.\textsuperscript{31,33} Two cohort studies were assessed as high quality\textsuperscript{27,58} and three as moderate.\textsuperscript{36,39,40} Detailed quality assessments are provided in Online Supplementary Document.

INTRAVAGINAL PRACTICES AND HPV INFECTION

Eleven studies examined the association between IVPs and HPV infection, of which six assessed douching\textsuperscript{30–33,38,40} and five assessed intravaginal cleansing or insertion (Table 2).\textsuperscript{23,24,28,29,39} A clear definition of the IVP was only given in five studies.\textsuperscript{23,24,28,29,31} The prevalence of intravaginal insertion was much less than that observed for intravaginal cleansing, ranging from 0.2–32.1% and 20.9–94% respectively,\textsuperscript{23,29,39} while that of douching ranged from 41.3–97.1%.\textsuperscript{31,33} Most studies focused on the likelihood of HPV detection and prevalence, which ranged from 7.9% in a South Korean study to 76.5% in a study conducted in South Africa,\textsuperscript{30,39} with the exception of one study assessing the likelihood of HPV redetection after documented clearance.\textsuperscript{38}

Six studies demonstrated evidence of a harmful association, with the greatest effect measure recorded from a study conducted in Haiti with an adjusted odds ratio (OR) of 5.01 (95% CI 1.56–16.05), between douching with a pigeon pea infusion and HPV infection.\textsuperscript{31} Four found moderate associations, with one finding that douching was significantly associated with infection with a higher number of HPV subtypes,\textsuperscript{24} and the remaining three reported associations with increased risk of HPV infection and prevalence.\textsuperscript{29,32,35} Douching was also associated with a higher likelihood of HPV type-16 (high-risk subtype) redetection.\textsuperscript{38} One study showed an association between IVPs and HPV prior to sexual debut (OR 2.19, 95% CI 1.09–4.39), although the authors proposed that this might be due to underreporting of self-reported sexual activity.\textsuperscript{29}

Protective associations were suggested in two studies: one found frequent douching was associated with a lower prevalence of HPV infection; the other found that regular intravaginal washing, especially when occurring post-coital was associated with infection with lower numbers of HPV subtypes.\textsuperscript{23,30} There was no evidence to support an association between douching, intravaginal cleansing or insertion and HPV infection in two studies.\textsuperscript{28,40} The negative finding for intravaginal insertion may have been due to the low prevalence reported in the study populations; 5% in Malawi and 5.5% in Cambodia, which were likely underpowered to detect associations.\textsuperscript{23,28}

Cervical disease was assessed on the spectrum from low-to high-grade dysplasia and subsequent invasive cervical carcinoma, with seven studies examining associations with IVPs (Table 3), of which three provided clear definitions of the IVPs under investigation.\textsuperscript{34,36,42} Four studies assessed douching\textsuperscript{25,37,41,42} and three assessed intravaginal cleansing and insertion.\textsuperscript{34–36} The prevalence of cervical changes varied from 6.1% in Taiwan\textsuperscript{37} to 24.6% in Nigeria.\textsuperscript{25}

Of the four studies evaluating douching, three found this practice to be associated with a higher risk of cervical disease. One study carried out among a female sex worker (FSW) cohort in Nigeria found that although vaginal douching with lemon or lime juice was significantly associated with the detection of high-grade squamous intraepithelial lesion (HSIL) (OR 2.13, 95% CI 1.03–4.40, \textit{P}=0.025), the strength of this association lessened when combined with low-grade squamous intraepithelial lesion (LSIL) (OR 1.76, 95% CI 1.0–3.10, \textit{P}=0.042).\textsuperscript{45} In a study examining douching and carried out in the USA, douching frequency (>4 times/month) was found to be associated with increased risk of in-situ and invasive cervical carcinoma (adjusted OR 4.7, 95% CI 1.9–11).\textsuperscript{41} In another study, carried out in Taiwan, although douching after sexual intercourse was found to be associated with the non-regression of LSIL, this was not maintained as a risk factor for progression.\textsuperscript{37}

Two out of three studies found evidence of a harmful association between intravaginal cleansing and insertion, and cervical disease. Use of herbs for intravaginal insertion in Zimbabwe was found to be associated with cervical dyskaryosis (aOR 2.16, 95%CI 1.18–4.61).\textsuperscript{32} Similarly, insertion of plant products was associated with LSIL or poorer outcomes in a study in the DRC (aOR 2.70, 95% CI 1.04–7.01).\textsuperscript{34} A third study, although suggestive of a positive association for the use of finger cleansing, intravaginal wiping and inserting traditional substances with dysplasia on Pap smear, did not reach significance in adjusted analyses (RR 2.42, 95%CI 1.00–5.90, \textit{P}=0.050).\textsuperscript{36} Use of IVPs was almost universal in this study population, which may have limited the ability to detect associations.\textsuperscript{36}
| Author, year of publication, country | Outcome | Outcome prevalence (%) | Intravaginal practice & prevalence (%) | Effect measure of association |
|-------------------------------------|---------|------------------------|----------------------------------------|-------------------------------|
| Bui et. al, 2018 Cambodia           | HPV infection (number of infecting HPV genotypes) | 47.0 | Intravaginal washing: 90 Intravaginal wiping: 29 Intravaginal insertion: 5.5 | Ever performed intravaginal washing: IRR 0.59 [95% CI 0.41 – 0.85], P = 0.005  Often performed intravaginal washing shortly before vaginal sex in lifetime: IRR 0.92 [95% CI 0.85 – 1.01], P = 0.086  Often performed intravaginal washing shortly after vaginal sex in lifetime: IRR 0.88 [95% CI 0.81 – 0.97], P = 0.007  No significant associations for the solution used for intravaginal washing  Ever performed intravaginal insertion: IRR 0.81 [95% CI 0.43 – 1.42] |
| Bui et. al, 2016 USA                | HPV infection (number of infecting HPV DNA types) | 48.6 | Douching*: 23 | Douched in past 6 months & higher number of HPV DNA types: RRR 1.56 [95% CI 1.28 – 1.90], P <0.001  Frequency of douching in the past 6 months (unadjusted analyses): <1 time/month (82 participants): RRR 1.49 [1.09 – 2.05], P=0.013  1 time/month (91 participants): RRR 1.54 [1.14 – 2.09], P=0.005  2-4 times/month (85 participants): RRR 1.63 [1.21 – 2.21], P=0.002  5 or more/month (7 participants): RRR 1.77 [0.71 – 4.42], P = 0.22 |
| Ebrahim et. al, 2016 South Africa   | HPV prevalence | 76.3 | Vaginal insertion practices: 32.1 | Vaginal insertion practices & HPV infection: Crude OR: 2.12 [95% CI 1.02 – 4.41], P = 0.045  Adjusted OR: 1.98 [95% CI 0.88 – 4.48], P = 0.099 |
| Esber et. al, 2016 (full publication) Malawi | High-risk HPV infection | 22 | Intravaginal cleansing:  With soap & water: 47  With cotton, cloth or tissue: 94 Intravaginal insertion: 5 | Cleansing with soap and water: PR 1.03 [95% CI 0.51 – 2.08]  Cleansing with cotton, cloth or tissue: PR 0.73 [95% CI 0.25 – 2.08]  Other products: PR 1.96 [95% CI 0.69 – 5.5]  IVP frequency and hr-HPV:  Any IVP: PR 0.98 [95% CI 0.52 – 1.85]  Soap and water: PR 0.48 [95% CI 0.19 – 1.20] |
| Houlihan et. al, 2014 (full publication) Tanzania | HPV infection | 8.4 | Intravaginal cleansing: 20.9 Intravaginal insertion: 0.2 | Intravaginal cleansing: aOR 2.19 [95% CI 1.09 – 4.39]  Dose-response relationship between cleansing frequency and HPV DNA detection: aOR 1.54 [95% CI 1.17 – 2.03] |
| Lee et. al, 2014 South Korea        | HPV infection | 7.9 | Douching: 92.5 | Douching:  Every other day or more: OR 0.32 [95% CI 0.13 – 0.77]  1 – 2 times/month: OR 1.79 [95% CI 0.13 – 24.38] |
| Moscicki et. al, 2013 USA          | HPV16 DNA redetection on cervical sample | 18.1 redetection within 8.5 years | Douching: Not reported | Association of douching with redetection of human papillomavirus Type 16 (HPV16) DNA Among Women who had evidence of HPV16 DNA infection and clearance: aOR 2.35 [95% CI 1.02 – 5.41] |
| Seay et. al, 2017 (full publication) Haiti | High-risk HPV infection | 11 | Douching: 97.1 | Douching with pigeon pea infusion & high-risk HPV: aOR 5.01 [95% CI 1.56 – 16.05] |
| Shaw et. al, 2016 Brazil            | HPV 1-year period prevalence: transient HPV infection, persistent HPV infection | 39.3 | Douching: Not reported | Douching frequent vs. infrequent & Subgenus 2 (carcinogenic) HPV: OR 1.29 [95% CI 0.83 – 2.00]  Douching frequent vs. infrequent: OR 1.10 [95% CI 0.60 – 2.00] for transient infection, 1.12 [95% CI 0.62 – 2.01] for persistent infection  No association for substance used (Natural/Medical/Unknown) |
| Sun et. al, 2005                    | HPV prevalence | 68.5 | Douching: 64.7 | Frequent vaginal douching: OR 1.48 [95% CI 1.12 – 1.97] |
| Author, year of publication, country | Outcome | Outcome prevalence (%) | Intravaginal practice & prevalence (%) | Effect measure of association |
|-------------------------------------|---------|-------------------------|----------------------------------------|-----------------------------|
| Taiwan                             | HPV infection | 64                      | Douching: 41.3                          | Douching during the last 90 days: aOR 2.1 [95% CI 1.2 – 3.6] |
| Tarkowski et. al, 2004 USA         | HPV infection | 64                      | Douching: 41.3                          | Douching frequency during the last 90 days: |
|                                     |          |                         |                                        | • 0: OR 1.6 [95% CI 0.9 – 3.1] |
|                                     |          |                         |                                        | • 1 or 2: OR 2.6 [95% CI 1.4 – 5.0] |
|                                     |          |                         |                                        | • 3 or more: OR 5.2 [95% CI 2.4 – 11.2] |

- aOR – adjusted odds ratio; HPV – human papillomavirus; hrHPV – high risk human papillomavirus; IRR – incidence rate ratio; OR – odds ratio; PR – prevalence ratio; RRR – relative risk ratio; 95% CI – 95% confidence interval
### Table 3: Study results – cervical disease

| Author, year of publication, country | Outcome | Outcome prevalence (%) | Intravaginal practice & prevalence (%) | Effect measure of association |
|-------------------------------------|---------|-------------------------|----------------------------------------|-----------------------------|
| Ali-Risasi et al., 2015 DRC          | Low-grade squamous intraepithelial lesions or worse | 7.5 | Use of plants for vaginal care: 11.4 | Use of plants for vaginal care: aOR 2.70 [95% CI 1.04 – 7.01] |
|                                     | In afraid prevalence (%) | | Use of chemical products for vaginal care: 26.0 | Use of chemical products for vaginal care: aOR 0.65 [95% CI 0.37 – 1.14] |
| Bayo et al., 2002 Mali               | Invasive Cervical Carcinoma | N/A, case-control study | Douching: • Cases: 3.7 | Never having practiced vaginal douching & cervical cancer: aOR 17.6 [95% CI 4.2 – 74.7] |
| Chu et al., 2011 Taiwan              | Non-regression or progression of LSIL | 6.1 non-regression, 10.5 progression | Douching: 65 | Habit of douching after vaginal intercourse: OR 1.89 [95% CI 1.01 – 3.53] |
|                                     | | | | • With tap water: OR 1.77 [95% CI 0.94 – 3.35] |
|                                     | | | | • With saline or detergent: OR 3.14 [95% CI 1.04 – 9.49] |
| Gardner et al., 1991 USA            | In-situ and invasive cervical carcinoma | N/A, case-control study | Douching: • Cases: 69 | Douching 10 or more times in the lifetime & cervical carcinoma: |
|                                     | | | | • Crude OR 2.5 [95% CI 1.8 – 3.6] |
|                                     | | | | • Adjusted OR 1.3 [95% CI 0.8 – 1.9] |
|                                     | | | | Douching frequency, only >4 times/month associated: |
|                                     | | | | • Crude OR 6.7 [95% CI 3.6 – 13] |
|                                     | | | | • Adjusted OR 4.7 [95% CI 1.9 – 11] |
|                                     | | | | No specific douching preparations were associated with an increased risk |
| Mbizvo et al., 2005 Zimbabwe         | Cervical dyskaryosis (mild, moderate, severe) | 19 (16 mild, 1.5 moderate, 1.5 severe) | Intravaginal cleansing: 48 | Intravaginal cleansing & cervical dyskaryosis: aOR 2.1 [95% CI 1.10 – 4.2] |
|                                     | | | Use of intravaginal herbs: 27 | Use of intravaginal herbs & cervical dyskaryosis: aOR 2.16 [95% CI 1.18 – 4.61] |
| Sagay et al., 2009 Nigeria           | Squamous intraepithelial lesions (SILs) | 24.6 | Douching: • With lime juice: 90.4 | Douching with lemon/lime juice & HSIL: aOR 2.13 [95% CI 1.03 – 4.40], P = 0.025 |
|                                     | | | • With lemon juice: 14.2 | Douching with lemon/lime juice & LSIL/HSIL: aOR 1.76 [95% CI 1.0 – 3.10], P = 0.042 |
|                                     | | | | Cervical dysplasia was not associated with greater duration of douching with lemon/lime juice: P-value for trend = 0.20 |
| van de Wijgert et al., 2000 Zimbabwe | Dysplasia on Pap smear | 17.3 in users, 15.3 non-users at follow-up | Intravaginal cleansing: 96 | Dysplasia on Pap smear in users vs. non-users: RR 3.14 [95% CI 0.85 – 13.33] |
|                                     | | | Intravaginal insertion: 47 | On multivariate analysis: OR 2.42 [95% CI 1.00 – 5.90] |

aOR – adjusted odds ratio; DRC – Democratic Republic of the Congo; HSIL – high-grade squamous intraepithelial lesion; LSIL – low-grade squamous intraepithelial lesion; OR – odds ratio; 95% CI – 95% confidence interval

---

### INTRAVAGINAL PRACTICES AND HIV INFECTION

We identified two studies that examined the association between IVPs and HIV infection (Table 4), both of which provided clear definitions of IVPs. One was carried out in China among female sex workers, the other in Uganda among women involved in high-risk sexual behaviours.26,27 Weak positive associations were demonstrated between intravaginal cleansing and HIV prevalence in both studies, finding adjusted odds ratios of 2.29 (95% CI 1.01–5.25) and 1.32 (95% CI 1.00–1.73), P = 0.05 respectively.26,27 The use of toothpaste and medical disinfectant were the only statistically significant associations.26 Similarly, this was observed for intravaginal cleansing with soap in the Ugandan study.27

We examined whether or not HIV infection was explored in the studies investigating associations between IVPs with HPV and cervical disease (Online Supplementary Document): less than half the studies stratified by HIV status; none found a significant relationship.

### POTENTIAL MODERATOR VARIABLES

We examined potential moderator variables for association of IVPs with the outcomes of interest (Table 5). Seven studies assessing association with HPV infection...
described the substances used, with all except one, further analysing associations with each of the substances separately. A positive association was demonstrated in two studies: in one, normal saline or detergent use for douching was found to be more harmful than tap water in adjusted analyses; in the other, an association between douching and a higher risk of HPV infection was found with a pigeon pea infusion. Four studies did not find statistically significant associations between the substances used for douching, intravaginal cleansing or intravaginal insertion and the risk of HPV infection. The frequency of IVP use was examined in seven studies, with three reporting a positive dose-response effect: the higher the frequency of the IVP use, the higher the likelihood of HPV infection. The remaining studies did not demonstrate an association between increasing frequency of IVP use and the likelihood of HPV infection, but one found that the highest frequency of douching was protective for HPV infection.

In terms of potential moderators for an association of IVP use and cervical disease, only three studies analysed by the specific IVP substance used. One study found higher odds of LSIL non-regression with saline or detergent (OR 3.14, 95% CI 1.04–9.49) compared to tap water (OR 0.77, 95% CI 0.94–3.35). Another comparison of chemical and commercial solutions, water alone, and water in combination with vinegar or soda found risk did not depend on the substance used. In the third study, although the use of chemicals was more prevalent than plant products (26% vs. 11%), only plant products had a significant association with the presence of LSIL or more severe lesions, with an adjusted odds ratio of 2.70, 95% CI 1.04–7.01. Two studies reported on timing of IVP use. Post-coital vaginal douching was found to be associated with harm, but no comparisons were made with pre-coital timing. The second study mentioning timing did not analyse pre-coital and post-coital timing separately and instead considered douching as a whole.

Two studies commented on the duration for which IVPs were used; a study evaluating an FSW cohort noted that although douching with lemon or lime juice was closely associated with the duration for which participants had been employed in commercial sex work, this did not seem to have an impact on the likelihood of cervical disease; the other study, although reporting on duration did not analyse its impact on the associations.

**DISCUSSION**

**SUMMARY OF FINDINGS**

Overall, the current evidence base does not allow firm conclusions to be drawn on the association between IVPs, HPV infection or the development of cervical cancer, although there is a broad suggestion of harm. This systematic review included 20 studies in 23 publications of which most were of low to moderate quality. As most studies involved douching, drawing associations between the outcomes of interest and other types of IVPs was limited.

The prevalence of IVPs was high in most study populations, but with wide variation in the specific practice, and by geographic location. Douching or intravaginal cleansing were much more common than intravaginal insertion in general, reflecting findings from previous studies. Eleven out of 18 studies reported an elevated risk of HPV infection, or cervical disease, with IVP use. However, it was not possible to draw firm conclusions of association between HPV infection and either intravaginal cleansing or insertion, similar to findings demonstrated in relation to HIV infection. In contrast, there is some evidence of increased risk of cervical disease, with both intravaginal cleansing and insertion.
| Author, Year    | Outcome      | IVP                                      | Clear definition of IVP | Description of substance used | Method of application | Purpose | Timing | Frequency | Duration |
|----------------|--------------|-----------------------------------------|-------------------------|-------------------------------|-----------------------|---------|--------|-----------|----------|
|                |              |                                         |                         |                               |                       |         |        |            |          |
| **HPV Infection** |              |                                         |                         |                               |                       |         |        |            |          |
| Bui et. al, 2018 | HPV          | Intravaginal washing, wiping & insertion | ✓                       | ✓                             | ✓                     | ✓       | ✓      | ✓         | ✓        |
| Bui et. al, 2016 | HPV          | Douching (analysed as intravaginal cleansing) | ✓                       | -                             | -                     | -       | -      | ✓         | -        |
| Ebrahim et. al, 2016 | HPV       | Intravaginal substance use/ vaginal insertion practice | -                       | ✓                             | ✓                     | -       | -      | -         | -        |
| Esber et. al, 2016 | HPV          | Intravaginal cleansing & insertion       | ✓                       | ✓                             | ✓                     | -       | -      | ✓         | -        |
| Houlihan et. al, 2014 | HPV       | Intravaginal cleansing & insertion       | ✓                       | ✓                             | ✓                     | -       | -      | ✓         | -        |
| Lee et. al, 2014  | HPV          | Douching                                | -                       | -                             | -                     | -       | -      | ✓         | -        |
| Moscicki et. al, 2013 | HPV      | Douching                                | -                       | -                             | -                     | -       | -      | -         | -        |
| Seay et. al, 2017  | HPV          | Douching                                | ✓                       | ✓                             | ✓                     | ✓       | -      | -         | -        |
| Shaw et. al, 2016  | HPV          | Douching                                | -                       | ✓                             | -                     | -       | -      | ✓         | -        |
| Sun et. al, 2005   | HPV          | Douching                                | -                       | ✓                             | -                     | -       | ✓      | -         | -        |
| Tarkowski et. al, 2004 | HPV       | Douching                                | -                       | -                             | -                     | ✓       | -      | -         | -        |
| **Cervical disease** |              |                                         |                         |                               |                       |         |        |            |          |
| Ali-Risasi et. al, 2015 | LSIL or worse | Plants & chemicals for vaginal care    | ✓                       | ✓                             | -                     | -       | -      | -         | -        |
| Bayo et. al, 2002  | Invasive cervical carcinoma | Douching                       | ✓                       | ✓                             | -                     | -       | -      | -         | -        |
| Chu et. al, 2011   | Non-regression or progression of LSIL | Douching                       | -                       | ✓                             | -                     | -       | ✓      | -         | -        |
| Gardner et. al, 1991 | In-situ and invasive cervical carcinoma | Douching                       | -                       | ✓                             | ✓                     | -       | ✓      | -         | -        |
| Mbizvo et. al, 2005 | Cervical dyskaryosis | Intravaginal cleansing & insertion | -                       | -                             | -                     | ✓       | -      | -         | -        |
| Sagay et. al, 2009  | Squamous intraepithelial lesions | Douching                       | -                       | ✓                             | -                     | ✓       | -      | -         | -        |
| van de Wijger et. al, 2000 | Dysplasia on Pap smear | Intravaginal cleansing, wiping & insertion | ✓                       | ✓                             | ✓                     | ✓       | -      | -         | ✓        |
| **HIV Infection**   |              |                                         |                         |                               |                       |         |        |            |          |
| Luo et. al, 2016    | HIV          | Douching (analysed as intravaginal cleansing) | ✓                       | ✓                             | -                     | ✓       | -      | -         | -        |
| Author, Year       | Outcome | IVP                                      | Clear definition of IVP | Description of substance used | Method of application | Purpose | Timing | Frequency | Duration |
|-------------------|---------|-----------------------------------------|-------------------------|-------------------------------|-----------------------|---------|--------|-----------|----------|
| Vandepitte et. al, 2011 | HIV     | Intravaginal cleansing & insertion      | ✓                       | ✓                             | -                     | ✓       | -      | -         | -        |

Adapted from Popay et. al, 2006 p.39

✓: given in the study
-: not reported

HIV – human immunodeficiency virus; HPV – human papillomavirus; IVP – intravaginal practice; LSIL – low-grade squamous intraepithelial lesion
STRENGTHS AND LIMITATIONS OF THE STUDY

The main strengths of our review included the comprehensive search strategy, and searching of six databases as well as grey literature sources. A diverse range of studies covered varying geographical locations, with the inclusion of over 14,000 participants, and good representation of women from the general population as well as female sex workers. Quality assessment was carried out using validated tools.

Limitations to our systematic review are important to note. At present, most evidence lies in cross-sectional studies and therefore the detection of HPV infection was only limited to recently acquired infections which may have been transient. The inability to establish temporality limited clear understanding of the possible mechanism of association as the persistence of HPV infection is a pre-requisite for progression to cervical cancer. The substantial heterogeneity brought about by the absence of use of clear definitions for IVPs and detail regarding their specific application also limits an understanding of the potential association. In addition, there is the possibility of attenuated risk occurring where multiple IVPs were undertaken in the same study population, but it was not possible to disaggregate data. Douching was the most frequently studied practice, with limited data on intravaginal cleansing practices or intravaginal insertion: reporting of these may be influenced by social desirability bias. Although the geographical diversity captured is recognised as a strength and similarities were noted across different countries, it is important to acknowledge that certain context-specific nuances with respect to IVPs may not have been comprehensively reflected, given their culturally engrained nature.

EXISTING LITERATURE

We have identified no previous systematic reviews on IVP use and risk of cervical disease: a meta-analysis from 1997 examined the relationship between douching and cervical cancer and found a marginal association. That study reported pooled results from six case-control studies with invasive cervical cancer as the outcome and suggested that associations could be related to the preparation used for douching, as well as the frequency and timing. However, due to the length of time required for the development of cervical cancer, we instead considered possible associations between the acquisition of HPV infection, and subsequent progression to cervical cancer, with a variety of IVPs in addition to douching. Exploration of the effect of potential moderator variables was limited in our review due to the lack of detail in reporting in the primary studies and findings were mixed. The specific substance used for IVPs could possibly contribute to a higher risk of HPV infection or changes leading to persistence and cervical cancer development through the chemical content or degree of abrasiveness. In our review, nine studies analysed this variable: four showed evidence of an increased risk. However, there was considerable heterogeneity in the substances assessed, from normal saline, toothpaste and disinfectants to various plant and commercial products.

Similarly, the frequency of undertaking IVPs was inconclusive, likely contributed to by the inconsistencies in definitions for ‘frequent’ and ‘infrequent’, with some measuring daily frequency and others assessing conduct of IVPs over a weekly or monthly basis. The frequency of use had been hypothesised to be an important factor in relation to douching and the acquisition of bacterial STIs and other negative outcomes, possibly due to the decreased time for recovery of the vaginal flora with more frequent conduct of IVPs. Other factors, such as timing and duration of use of IVPs could not be clearly assessed as they were not consistently reported in the included studies.

There is limited new evidence of association of IVPs and HIV infection since 2008, with the identification of only two full-text studies. Consistent with previous findings, both studies reported harm associated with intravaginal cleansing, but one reported no association with intravaginal insertion. A conference abstract (excluded at full-text stage), suggests decreased risk of HIV infection with intravaginal cleansing.

IMPLICATIONS

There is a need for prospective longitudinal studies in populations where IVPs are prevalent, to better understand whether and how IVPs may affect the timeline of progression to cervical cancer, or other gynaecological outcomes. Given that most evidence lies in low to moderate quality studies, future studies should include larger and more representative samples. In addition, consistent use of standardised definitions and categorisations of IVPs, such as those proposed by the WHO GSVP study group, would enable clearer comparisons between populations and regions. It is essential to limit the effects of social desirability and recall bias in reporting, using contextually and culturally appropriate methods to elicit understanding and reporting of the types of IVPs (such as the self-administered pictorial diary used in Uganda and Tanzania).

Exploration of mediating factors for risk should also be improved. An association between HIV infection and IVPs has been proposed to be related to an increased risk of abnormal flora, in particular bacterial vaginosis which could then facilitate transmission, rather than a direct linkage. Bacterial vaginosis has been investigated in two prior systematic reviews exploring associations with HPV infection as well as with cervical intraepithelial neoplasia. However, these studies did not investigate IVPs, so there remains scope for investigation of this and other potential mediators.

Although the precise mechanism remains unclear, the extent of the evidence suggestive of harm in the included studies in this review is a cause for concern. In keeping with previous studies, a high prevalence of IVPs was described in most of the included studies, although this differed depending on the practice described. With the majority of participants in the included studies recruited from health care facilities, it has been proposed that health professionals may be well positioned to ascertain whether IVPs are utilised and to promote education and awareness about their possible risk. Some scholars have proposed group delivered interventions for peer support and motivation to facilitate discussion, and possibly cessation, of IVPs may be effective.
Health education interventions about the potential risk of IVPs have often been implemented in the context of HIV infection,\textsuperscript{53,56} where the importance of using culturally sensitive and acceptable approaches are well-recognised. This approach could be further adapted to include messages about HPV infection and cervical cancer development. Given that IVPs tend to be socially and culturally engrained, sensitivity is required in understanding their motivating and perpetuating factors and the beliefs surrounding their benefits as well as any cervical cancer risk.\textsuperscript{5,52,56} In addition, a clear distinction should be made between evidence-based practices that may involve intravaginal insertion, such as the clinical use of vaginal suppositories for treating infection and contraceptive vaginal rings\textsuperscript{57,58} from the potentially more harmful insertion practices described in this review. This issue has been a source of concern in some study populations, amongst whom beliefs exist that any product applied intravaginally, even if medically indicated, could be harmful.\textsuperscript{52} It will be important to promote clear public health advice on this topic going forwards, particularly with the potential advent of new evidence-based intravaginal devices such as antiretroviral intravaginal rings for HIV pre-exposure prophylaxis which have been undergoing clinical trials.\textsuperscript{59–61}

CONCLUSIONS

The ability to draw firm conclusions regarding an association of IVPs with HPV infection, or the development of cervical cancer, was limited by the current evidence base. Although the possibility of harm was suggested overall, IVPs were not clearly defined in the identified studies and there was limited capacity to assess mediators of the pathway. It may be necessary to increase awareness related to potential risks of IVPs and to conduct these efforts with cultural sensitivity, but this must be substantiated by more robust evidence to ensure that clear and consistent messages are promoted.
REFERENCES

1. World Health Organization (WHO). *A Multi-Country Study on Gender, Sexuality and Vaginal Practices: Implications for Sexual Health: Policy Brief*. Geneva: World Health Organization; 2012. https://apps.who.int/iris/handle/10665/75182. Accessed May 3, 2019.

2. Hilber AM, Hull TH, Preston-Whyte E, et al. A cross-cultural study of vaginal practices and sexuality: Implications for sexual health. *Soc Sci Med*. 2010;70(3):392-400. doi:10.1016/j.socscimed.2009.10.023

3. Zhang J, Thomas AG, Leybovich E. Vaginal douching and adverse health effects: A meta-analysis. *Am J Public Health*. 1997;87(7):1207-1211. doi:10.2105/ajph.87.7.1207

4. Hilber AM, Francis SC, Chersich M, et al. Intravaginal Practices, Vaginal Infections and HIV Acquisition: Systematic Review and Meta-Analysis. Horsley T, ed. *PLoS ONE*. 2010;5(2):e9119. doi:10.1371/journal.pone.0009119

5. Menard J, Kobetz E, Diem J, Lilfleur M, Blanco J, Barton B. The sociocultural context of gynecological health among Haitian immigrant women in Florida: Applying ethnographic methods to public health inquiry. *Ethn Health*. 2010;15(3):255-267. doi:10.1080/13557851003671761

6. Brown JE, Brown RC. Traditional Intravaginal Practices and the Heterosexual Transmission of Disease: A Review. *Sex Transm Dis*. 2000;27(4):183-187. doi:10.1097/00007435-200004000-00001

7. Schwandt M, Morris C, Ferguson A, Ngugi E, Moses S. Anal and dry sex in commercial sex work, and relation to risk for sexually transmitted infections and HIV in Meru, Kenya. *Sex Transm Infect*. 2006;82(5):392-396. doi:10.1136/sti.2006.019794

8. Buve A, Jespers V, Crucitti T, Fichorova RN. The vaginal microbiota and susceptibility to HIV. *AIDS*. 2014;28(16):2353-2344. doi:10.1097/qad.0000000000004452

9. Low N, Chersich MF, Schmidlin K, et al. Intravaginal Practices, Bacterial Vaginosis, and HIV Infection in Women: Individual Participant Data Meta-analysis. Mofenson L, ed. *PLoS Med*. 2011;8(2):e1000416. doi:10.1371/journal.pmed.1000416

10. Ginsburg O, Bray F, Coleman MP, et al. The global burden of women’s cancers: A grand challenge in global health. *Lancet*. 2017;389(10071):847-860. doi:10.1016/s0140-6736(16)31392-7

11. Schiffman M, Wentzensen N. From Human Papillomavirus to Cervical Cancer. *Obstet Gynecol*. 2010;116(1):177-185. doi:10.1097/aog.0b013e3181e4629f

12. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. *IARC Monogr Eval Carcinog Risks Hum*. 2012;100(Pt B):1-441. https://www.ncbi.nlm.nih.gov/pubmed/23189750.

13. Chelimo C, Wouldes TA, Cameron LD, Elwood JM. Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer. *J Infect*. 2013;66(5):207-217. doi:10.1016/j.jinf.2012.10.024

14. Denny LA, Franceschi S, de Sanjosé S, Heard I, Moscicki AB, Palefsky J. Human Papillomavirus, Human Immunodeficiency Virus and Immunosuppression. *Vaccine*. 2012;30:F168-F174. doi:10.1016/j.vaccine.2012.06.045

15. Myers KO, Ahmed NU. The Role of HIV in the Progression through the Stages of the Human Papillomavirus to Cervical Pathway. *AIDS Rev*. 2018;20(2):94-1043. doi:10.24875/aidsrev.m18000021

16. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. *BMJ*. 2015;550:g7647-g7647. doi:10.1136/bmj.g7647

17. Higgins JP, Deeks JJ. Selecting studies and collecting data. In: Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011.

18. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. 2012. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed May 23, 2019.

19. Downes MJ, Brennan ML, Williams HC, Dean RS. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). *BMJ Open*. 2016;6(12):e011458. doi:10.1136/bmjopen-2016-011458
Are intravaginal practices associated with human papillomavirus and the development of cervical cancer? A systematic...
40. Shaw E, Ramanakumar AV, El-Zein M, et al. Reproductive and genital health and risk of cervical human papillomavirus infection: Results from the Ludwig-McGill cohort study. *BMC Infect Dis.* 2016;16(1):116. doi:10.1186/s12879-016-1446-x

41. Gardner JW, Schuman KL, Slattery ML, Sanborn JS, Abbott TM, Overall JC Jr. Is vaginal douching related to cervical carcinoma? *Am J Epidemiol.* 1991;133(4):368-375. doi:10.1093/oxfordjournals.aje.a115890

42. Bayo S, Bosch FX, de Sanjose S, et al. Risk factors of invasive cervical cancer in Mali [Facteurs de risque du cancer invasif du col de l’utérus au Mali]. *Int J Epidemiol.* 2002;31(1):202-209. doi:10.1093/ije/31.1.202

43. Hull T, Hilber AM, Chersich MF, et al. Prevalence, Motivations, and Adverse Effects of Vaginal Praties in Africa and Asia: Findings from a Multicountry Household Survey. *J Women’s Heal.* 2011;20(7):1097-1109. doi:10.1089/jwh.2010.2281

44. Francis SC, Baisley K, Lees SS, et al. Vaginal practices among women at high risk of HIV infection in Uganda and Tanzania: Recorded behaviour from a daily pictorial diary. Thorne C, ed. *PLoS ONE.* 2013;8(3):e59085. doi:10.1371/journal.pone.0059085

45. Chisembele M, Rodriguez VJ, Brown MR, Jones DL, Alcaide ML. Intravaginal practices among young HIV-infected women in Lusaka, Zambia. *Int J STD AIDS.* 2018;29(2):164-171. doi:10.1177/0956464717721438

46. Booth A, Mshelia S, Analo CV, Nyakang’o SB. Qualitative evidence syntheses: Assessing the relative contributions of multi-context and single-context reviews. *J Adv Nurs.* 2019;75(12):3812-3822. doi:10.1111/jan.14186

47. Bennett C, Kuhn AE, Haverkos HW. Human papillomavirus and tar hypothesis for squamous cell cervical cancer. *J Biosci.* 2010;35(3):331-337. doi:10.1007/s12058-010-0038-y

48. Martino JL, Vermund SH. Vaginal douching: evidence for risks or benefits to women's health. *Epidemiol Rev.* 2002;24(2):109-124. doi:10.1093/epirev/mxf004

49. Gillet E, Meys JFA, Verstraelen H, et al. Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: A meta-analysis. *BMC Infect Dis.* 2011;11(1):10. doi:10.1186/1471-2334-11-10

50. Gillet E, Meys JFA, Verstraelen H, et al. Association between Bacterial Vaginosis and Cervical Intraepithelial Neoplasia: Systematic Review and Meta-Analysis. Atashili J, ed. *PLoS ONE.* 2012;7(10):e45201. doi:10.1371/journal.pone.0045201

51. Martino JL, Youngpairoj S, Vermund SH. Vaginal Douching: Personal Practices and Public Policies. *J Women’s Heal.* 2004;15(9):1048-1065. doi:10.1089/jwh.2004.15.1048

52. McFarland DM. Beliefs about the causes of cervical cancer in Botswana: Implications for nursing. *Int Nurs Rev.* 2009;56(4):426-432. doi:10.1111/j.1466-7557.2009.00742.x

53. Alcaide ML, Rodriguez VJ, Fischl MA, Jones DL, Weiss SM. Addressing intravaginal practices in women with HIV and at-risk for HIV infection, a mixed methods pilot study. *Int J Womens Health.* 2017;9:125-132. doi:10.2147/iwjh.s158883

54. Masese L, McClelland RS, Gitau R, et al. A pilot study of the feasibility of a vaginal washing cessation intervention among Kenyan female sex workers. *Sex Transm Infect.* 2015;89(3):217-222. doi:10.1136/sextrans-2012-050564

55. Esber A, Moyo P, Munjomba M, et al. Cessation of intravaginal practices to prevent bacterial vaginosis: A pilot intervention in Zimbabwean women. *Sex Transm Infect.* 2015;91(3):183-188. doi:10.1136/sextrans-2014-051764

56. Alcaide ML, Chisembele M, Malupande E, et al. A bio-behavioral intervention to decrease intravaginal practices and bacterial vaginosis among HIV infected Zambian women, a randomized pilot study. *BMC Infect Dis.* 2017;17(1):338. doi:10.1186/s12879-017-2436-3

57. Brache V, Payán LJ, Faundes A. Current status of contraceptive vaginal rings. *Contraception.* 2013;87(3):264-272. doi:10.1016/j.contraception.2013.01.011

58. Monteiro I, Guazzelli CF, Bahamondes L. Advances in contraceptive vaginal rings: What does the future hold? *Expert Opin Pharmacother.* 2018;19(15):1685-1691. doi:10.1080/14656566.2018.1519549

59. Vincent KL, Moss JA, Marzinke MA, et al. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. Bekker L-G, ed. *PLoS Med.* 2018;15(9):e1002655. doi:10.1371/journal.pmed.1002655

Journal of Global Health Reports
60. Thurman AR, Schwartz JL, Brache V, et al. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women. Winston A, ed. PLoS ONE. 2018;13(6):e0199778. doi:10.1371/journal.pone.0199778

61. Palanee-Phillips T, Baeten JM. Topical delivery of long-acting antiretrovirals to prevent HIV acquisition. Curr Opin HIV AIDS. 2020;15(1):42-48. doi:10.1097/coh.0000000000000598
SUPPLEMENTARY MATERIALS

Online Supplementary Document
Download: https://www.joghr.org/article/21349-are-intravaginal-practices-associated-with-human-papillomavirus-and-the-development-of-cervical-cancer-a-systematic-literature-review/attachment/54441.docx